Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform’s Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth

Mar 31, 2020 | Press Releases

Animal studies show a complete and statistically significant (p <0.0001) inhibition of tumor growthMARLBOROUGH, Mass., March 31, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology...

Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update

Mar 26, 2020 | Press Releases

MARLBOROUGH, Mass., March 26, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene

Mar 10, 2020 | Press Releases

MARLBOROUGH, Mass. and MARTINSRIED/MUNICH, March 10, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™)...

Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering

Feb 13, 2020 | Press Releases

MARLBOROUGH, Mass., Feb. 13, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

Feb 11, 2020 | Press Releases

MARLBOROUGH, Mass., Feb. 11, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...